BMO Capital Markets Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price cut by BMO Capital Markets from $1,300.00 to $1,190.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 41.06% from the stock’s current price.

Several other equities research analysts have also recently commented on the company. Barclays lowered their target price on Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,260.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,090.24.

Regeneron Pharmaceuticals Stock Up 0.6 %

NASDAQ REGN opened at $843.60 on Friday. The stock has a fifty day moving average of $1,058.43 and a 200-day moving average of $1,039.88. The stock has a market capitalization of $93.00 billion, a P/E ratio of 20.88, a price-to-earnings-growth ratio of 2.88 and a beta of 0.15. Regeneron Pharmaceuticals has a 52 week low of $783.57 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.62 and a current ratio of 5.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the firm earned $8.79 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 37.46 EPS for the current year.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. SteelPeak Wealth LLC raised its stake in Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after buying an additional 692 shares during the period. Atria Investments Inc raised its stake in Regeneron Pharmaceuticals by 12.2% in the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after buying an additional 941 shares during the period. Tri Locum Partners LP raised its stake in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after buying an additional 8,949 shares during the period. Nordea Investment Management AB raised its stake in Regeneron Pharmaceuticals by 23.2% in the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after buying an additional 5,495 shares during the period. Finally, Tidal Investments LLC raised its stake in Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after buying an additional 711 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.